about
Glucose challenge test (50-g GCT) in detection of glucose metabolism disorders in peritoneal dialysis patients: preliminary study.Prevalence of Left Ventricular Hypertrophy and Left Ventricular Dysfunction in Older Renal Transplant Recipients.Type of Renal Replacement Therapy (Hemodialysis versus Peritoneal Dialysis) Does Not Affect Cytokine Gene Expression or Clinical Parameters of Renal Transplant Candidates.Progressive outer retinal necrosis in immunocompromised kidney allograft recipient.The influence of warm ischemia elimination on kidney injury during transplantation - clinical and molecular studyPretransplant Immune- and Apoptosis-Related Gene Expression Is Associated with Kidney Allograft FunctionPretransplantation cellular alloreactivity is predictive of acute graft rejection and 1-year graft function in kidney transplant recipients.Impact of donor-dependent genetic factors on long-term renal graft function.[Therapeutic use of potassium citrate].Catatonic episode after kidney transplantation.Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RT-PCR analysis.Successful embolization of the peripheral branches of the superior mesenteric artery performed because of tuberculosis-associated acute bleeding in a patient after a renal transplant.Predictive value of Banff score of early kidney allograft biopsies for 1-year graft survival.A significant role for anti-human leukocyte antigen antibodies and antibody-mediated rejection in the biopsy-for-cause population.Phenotypic risk factors for new-onset diabetes mellitus (NODAT) in renal transplant recipients.Advanced age of renal transplant recipients correlates with increased plasma concentrations of interleukin-6, chemokine ligand 2 (CCL2), and matrix metalloproteinase 2, and urine concentrations of CCL2 and tissue inhibitor of metalloproteinase 1.Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients.Lowering of Messenger Ribonucleic Acid Toll-Like Receptors 2-4,9 in Peripheral Blood Mononuclear Cells in Kidney Allograft Recipients, Relationships With Immunosuppressive Treatment, and Delayed Graft Function Occurrence.Reduction of lung congestion following arteriovenous fistula flow reduction in renal graft recipient.Intragraft mRNA expression of cytokines and growth factors in human kidney allograft biopsies by in situ RT-PCR analysis.Post-transplant Alternative Complement Pathway Activation Influences Kidney Allograft Function[Effect of ACE inhibitors on proteinuria and renal functioning in primary glomerulopathies][Effect of low-protein diet on the control of progression of chronic renal failure][Clinical evaluation of norfloxacin preparation in treatment of bacterial infections of the urinary tract in patients with various kidney diseases][Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin][Anti-neutrophil cytoplasmic antibodies ANCA in glomerulonephritis and systemic vasculitis with renal involvement--the frequency of occurrence and ability for granulocyte activation in vitro][Cytokines in kidney diseases--inflammation mediators and treatment targets][Gene expression of INF-gamma, IL-10, IL-2, IL-6, PDGF-B i TGF-beta in kidney tissue after renal transplantation][Prevention and therapy of ischemia-reperfusion injury in renal transplantation][Pathophysiology of ischemia-reperfusion injury in renal transplantation][Glomerulonephritis in neoplastic disease]Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysisPrimary idiopathic glomerulonephritis: modern algorithm for diagnosis and treatmentGlomerular lesion and increased cytokine gene expression in renal tissue in patients with decompensated nephrotic syndrome due to chronic GvHDImbalance of metallaproteinase/tissue inhibitors of metalloproteinase system in renal transplant recipients with chronic allograft injuryNon-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft lossComment on "Management of hypercalcemia after renal transplantation"The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes
P50
Q35221069-97D910C9-574D-4C6E-B028-A8D2ABEE22C3Q39518518-F4386979-D243-42CD-8DCF-A0D313260BEEQ40666715-260349E0-1074-4392-A7BB-94B37422A658Q41353067-77ACF4C0-98DC-404E-A3D5-38591DD0D618Q41659179-6A8E92B6-99D5-45CE-B8B2-3340A048BD72Q42534730-00C2D687-C1E8-4725-9072-EE9CE020D867Q43254726-D8AC038A-D9BC-4177-8E8A-49B8EB657689Q43688455-3169CDD6-6F31-4D28-BD77-07302568ADAFQ43689589-46FEAA73-1503-4BF6-A40F-6B7B2B842A74Q45066325-83AC1BB4-23D0-4663-89B4-D268E9AA484FQ46452689-C2EC3361-BC3B-4026-93E0-405371094C3CQ46516098-7F4F1A29-5E62-412F-A967-5EB5E5386E55Q46965979-27A50D89-9C2D-4A6C-BCDF-FFC8C0106542Q47578423-596188DF-864C-47FE-A1B6-C9A4395F6285Q48059651-EF52CCDD-D316-4D38-9996-87A75FA588B3Q51014731-9A2EEF10-62F7-42B8-A840-7BBC835A3893Q51014736-6A553927-BCEB-447C-86DD-9601A3D4936CQ51591102-FEDF737D-2B20-4B5D-8DBE-B4FF0A02E02BQ53484148-EB6CC7F8-5ADD-46F5-92AA-65AE42635304Q54668262-92B02908-385B-45F8-850C-AA163089CD08Q64245189-CA0A0E45-8596-4676-BFD0-40546624578DQ67836687-2B7E1BA9-8181-43DD-A02E-44D6AD8872BCQ70076310-3F75354C-1263-468B-8857-93C2ABB76D3DQ72200677-FF50D94C-A713-43B9-AEC2-3BA49818AD8FQ73630723-DD83646D-DB23-4179-84DF-FFECBD9AE08BQ77560237-DE712DBC-4FB9-49CE-A937-678E77BBEAAAQ78463059-189250AD-6FDD-4F6D-8F4E-5D192D360C23Q79402498-B553C949-416B-4E55-91A4-5E10EE66B17EQ79886503-22C57D88-488F-4461-B15F-99E27C930AF3Q79886508-E0C3BD25-82A8-4898-B4CD-3990CBF5021CQ81394919-807EEBA0-E744-45B5-A112-C9E108FDEB82Q81591077-EE306CD7-E8E5-4011-AB12-7DE83098FC5FQ83108292-A2507CB6-2748-4F7C-85C3-1F424DE12A4CQ84168082-CF2766EE-874B-4402-BA17-DB82F7229BC4Q85089656-08C825D7-ED1B-4237-B66F-B859254C4691Q85930767-4A287139-8BDB-4BE2-AA00-EC77DA3DA2B1Q86579323-6C2120F3-C108-4FD3-BA79-8661ED3ECB90Q86635362-622C88E4-79CF-4AD7-B54B-8FBE01075192
P50
description
researcher ORCID ID = 0000-0001-7669-7543
@en
wetenschapper
@nl
name
Oktawia Mazanowska
@ast
Oktawia Mazanowska
@en
Oktawia Mazanowska
@es
Oktawia Mazanowska
@nl
type
label
Oktawia Mazanowska
@ast
Oktawia Mazanowska
@en
Oktawia Mazanowska
@es
Oktawia Mazanowska
@nl
prefLabel
Oktawia Mazanowska
@ast
Oktawia Mazanowska
@en
Oktawia Mazanowska
@es
Oktawia Mazanowska
@nl
P31
P496
0000-0001-7669-7543